🩺 Evidence-Based Support for True Sense Continuous Glucose Monitoring (CGM)
True Sense CGM represents the next generation of real-time glucose monitoring technology, supported by major medical authorities and leading endocrinology research. It empowers users to track glucose trends continuously, make smarter health decisions, and achieve better diabetes management outcomes.
🌍 Global Medical Endorsements
1. American Diabetes Association (ADA, 2025)
The ADA recommends Continuous Glucose Monitoring (CGM) for all individuals with Type 1 diabetes and insulin-treated Type 2 diabetes.
Studies show significant improvements in time-in-range, reduced hypoglycaemia, and greater treatment satisfaction.
Source → ADA Standards of Care, 2025
2. National Institute for Health and Care Excellence (NICE, UK)
NICE advises using real-time CGM (rtCGM) or intermittently scanned CGM (isCGM) for adults and children living with diabetes, noting improved glycaemic stability and enhanced quality of life.
Source → NICE Guideline NG17, 2022
3. Endocrine Society & Williams Textbook of Endocrinology
Both sources recognise CGM as a superior tool to HbA1c testing for ongoing glucose management. It enables healthcare professionals and patients to personalise treatment plans based on real-time data.(Williams Textbook of Endocrinology, 14th Edition; Endocrine Society Guidelines, 2023)
📊 Clinical Evidence Supporting CGM
Recent clinical trials and meta-analyses highlight the proven benefits of Continuous Glucose Monitoring systems like True Sense CGM:
✅ Improved glycaemic control and reduced HbA1c
✅ Fewer severe hypoglycaemic episodes
✅ Increased patient confidence and adherence
✅ Better understanding of food, exercise, and medication effects
